To evaluate the anti-leukemia effects of metabolism-enhanced T cells, we performed a proof-of-principle exploration by directly co-culturing engineered T cells and either allogenic MV4-11, an AML blast cell line, or primary AML patient derived-CD33+ blasts in vitro. This evidence concerns the gene CD33 and acute myeloid leukemia.